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The present study aims to clarify the possible involvement of parvovirus B19 (B19V) infection
in rheumatoid arthritis (RA) pathogenesis by investigating the presence of B19V infection
markers (genomic sequences and virus-specific antibodies) in association with the level of
cytokines and RA clinical activity and aggressiveness. A total of 118 RA patients and 49 age-
and sex-matched healthy volunteers were enrolled in the study. Nested PCR was used to
detect B19V sequences in whole blood and cell-free plasma DNA, ELISA to detect virus-
specific antibodies and cytokine levels in plasma and recomLine dot blot assay for antibodies
to separate B19V antigens. The detection frequency of B19V DNA was higher in patients with
RA (25.4%) in comparison with healthy persons (18.4%). B19V DNA in cell-free plasma
(B19+p) was detected significantly often in RA patients in comparison with healthy controls
(13.6 vs 2%; P=0.0002). RA B19+p patients had higher disease activity and aggressiveness,
decreased haemoglobin and increased erythrocyte sedimentation rates. IL-6 plasma levels were
significantly higher in RA patients than in controls. Within the RA patients’ group the IL-6 level
was significantly increased in B19+p patients with disease activity scores of DAS28>5.2, high
C-reactive protein and low haemoglobin. Contrary to the healthy controls, the majority of RA
B19+p patients did not have antibodies to VP-1S (VP1u) and VP-N (N-terminal half of
structural proteins VP1 and VP2), which correspond to the epitopes of neutralizing antibodies.
These results indicate that B19V infection at least in some patients is involved in RA
pathogenesis.
INTRODUCTION
Human parvovirus B19 (B19V) is a small DNA virus with a
worldwide distribution. The genome of B19V consists of
single-stranded 5.6 kb DNA that encodes three large pro-
teins. The non-structural protein NS1 is composed of 671
aa. Structural capsid proteins VP1 and VP2 are encoded in
the same ORF with production of proteins of 84 and
58 kDa, respectively. VP1 and VP2 are identical, with the
exception of 227 aa at the amino-terminal end of the
VP1 protein, the so-called VP1-unique region (VP1u)
(Cotmore et al., 1986; Ozawa & Young, 1987; Ozawa et al.,
1987). B19V is normally transmitted through the respira-
tory route, but can also be transmitted from the mother to
the foetus (Berry et al., 1992; Brown et al., 1984; Clewley
et al., 1987; Kinney et al., 1988; Musiani et al., 1999),
through bone marrow (Cohen et al., 1997; Heegaard &
Laub Petersen, 2000; Ozawa & Young, 1987) and organ
transplantations (Bertoni et al., 1997; Lui et al., 2001), and
via transfused blood products (Juhl et al., 2014). B19V rep-
licates in red blood cell precursors in the bone marrow,
however, it could persist in other cells (Bratslavska et al.,
2015; Milla et al., 1993; Morey & Fleming, 1992; Söder-
lund-Venermo et al., 2002). B19V DNA was found in
peripheral blood and synovial fluid cells (Kozireva et al.,
2008), and VP1 protein was detected in synovial cells
Four supplementary tables and two supplementary figures are available
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including lymphocytes, macrophages and neutrophils
(Takahashi et al., 1998). Although antibodies to conforma-
tional and linear epitopes of VP1 and VP2 capsid proteins
were detected (Azzi et al., 2004; Corcoran et al., 2000; Man-
aresi et al., 1999, 2004; Söderlund et al., 1995), the most
important are neutralizing antibodies directed to the VP1u
and VP1–VP2 junction regions (Saikawa et al., 1993; Zuffi
et al., 2001).
B19V is associated with many clinical disorders. This virus
causes erythema infectiosum (fifth disease) in children.
B19V infection can be asymptomatic or can cause various
complications such as arthralgia, arthritis, transient aplas-
tic crisis and chronic anaemia in adults (Chorba et al.,
1986; Dijkmans et al., 1988; Lefrere et al., 1986; Reid
et al., 1985; White et al., 1985). There is some evidence
that B19V infection is more frequent in patients with cer-
tain autoimmune diseases [juvenile rheumatoid arthritis
(RA) (Oguz et al., 2002), systemic lupus erythematosus
(Hsu & Tsay, 2001), Sjögren’s syndrome (Ramos-Casals
et al., 2000), thyroiditis (Lehmann et al., 2008; Wang
et al., 2010) and chronic fatigue syndrome (Chapenko
et al., 2012)] and can even play a role in pathogenesis.
However, some publications suggesting that B19V does
not play any role in the pathogenesis, but may present a
clinical and serological tableau making it difficult to dis-
tinguish between a viral infection and systemic lupus
erythematosus (Moore et al., 1999; Seve et al., 2005).
Some authors did not find a link between B19V infection
and Sjögren’s syndrome (De Re et al., 2002; De Stefano
et al., 2003) or juvenile arthritis (Söderlund et al., 1997).
B19V infection is often associated with chronic arthritis,
although aetiologic associations with RA are conflicting
(Kerr, 2000; Takahashi et al., 1998).
RA is one of the most common inflammatory autoim-
mune diseases characterized by persistent synovitis, sys-
temic inflammation and production of autoantibodies
(Scott et al., 2010). The molecular mechanisms of RA
pathogenesis are not fully understood. It is believed that
approximately half of the risk factors for RA are attribut-
able to genetic factors such as the HLA alleles, while the
other half of the risks are environmental factors includ-
ing infection and smoking (Arleevskaya et al., 2014;
McInnes & Schett, 2011; Okada et al., 2014). Clinical
and animal model studies have suggested that infections
by many micro-organisms, such as Porphyromonas
gingivalis (Bartold et al., 2010; Hitchon et al., 2010), Pro-
teus mirabilis (Arabski et al., 2012), Epstein–Barr virus
(Mourgues et al., 2016) and mycoplasma contribute to
the aetiopathogenesis of RA (Durigon et al., 1993).
Higher rates of serological evidence of infections with
Epstein–Barr virus and cytomegalovirus were detected in
RA patients than in population controls (Magnusson
et al., 2010; Meron et al., 2010).
The aim of the present study was to clarify the possible
involvement of B19V infection in RA pathogenesis by
investigating the presence of B19V infection markers in
association with RA clinical activity and the level of
cytokines.
RESULTS
Frequency of B19V DNA in RA patients and
healthy controls
In this study we investigated the frequency of B19V
infection markers in the blood of RA patients. The
B19V genomic DNA was determined in whole blood
and cell-free plasma (Table 1). Persons in whose blood
or plasma B19V DNA was detected were named B19+.
If virus DNA was not detected, such persons were
named B19 . The mean age of B19+ and B19  RA
patients and control groups’ individuals was 58.3±13.6
and 58.3±13.0 years and 55.3±9.0 and 49.2±11.3 years,
respectively. The frequency of B19V DNA was higher in
patients with RA (30/118; 25.4%) in comparison with
control group individuals (9/49; 18.4%). The same ten-
dency was observed in both males [6/19 (31.6%) of RA
patients and 2/12 (16.7%) of controls were B19V DNA
positive] and females [24/99 (24.2%) of RA patients
and 7/37 (18.9%) of controls were B19V DNA posi-
tive]. B19V DNA was detected in whole blood (B19+b),
cell-free plasma (B19+p) or both whole blood and
plasma (B19+b/p). Table 1 shows the localization of
virus DNA in all investigated groups. In RA patients
B19V DNA was mostly found in the cell-free plasma
(53% from all B19+), while in the control group the
virus DNA was found mostly in the whole blood (89%
from all B19+). Our results showed that the frequency
of B19V latent/persistent (B19V sequences presented
only in DNA extracted from the whole blood) and
active (B19V sequences presented in DNA extracted
from the cell-free blood plasma) infection markers is
different in RA patients and healthy people
(Table S1, available in the online Supplementary Mate-
rial). We investigated how the localization of virus DNA
(blood and plasma, blood or plasma) correlates with
B19V seroprevalence and antibody spectrum, the level
of cytokines in plasma and disease clinical activity.
Table 2 shows the clinical characteristics [white blood
cells (WBC), haemoglobin (HgB), erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), cyclic
citrullinated peptide antibody (anti-CCP), disease activity
score (DAS28), disease duration and rheumatoid factor
(RF) result] of RA patients according to virus DNA
localization. RA patients (68.8%) from the B19+p group
were strongly positive (>60 EUml 1) for anti-CCPs,
while only 25% of B19+b/p, 33.3% of B19+b and
48.9% of B19  patients had anti-CCP levels
>60 EUml 1 (Table 2). Also, 68.8% of RA patients
from the B19+p group had high disease activity scores
(DAS28>5.2). There were no more than 50% of
patients with DAS28>5.2 in the groups B19+b, B19+b/p
and B19 . A higher percentage of patients from the RA
B19+p group had decreased HgB (68.8%) and increased
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ESR (87.5%), in comparison with persons in the other
groups. The presence of B19V DNA in RA patients did
not influence the expression of RF, disease duration or
CRP level (Table 2).
Antibodies to B19V antigens in the plasma of RA
patients and healthy controls
Antibodies to the main capsid protein VP2 were deter-
mined in the plasma of all investigated (118 RA and 49
controls) persons using the Biotrin ELISA kit (Tables 3
and S2). The percentages of RA and control persons
carrying antibodies to VP-2P, VPN, VP-1S (VP1u), VP-
2r, VP-C and NS-1 are shown in Table 3. The individ-
ual raw data are shown in Table S2. Table 3 shows that
the majority (78–90%) of subjects (healthy controls and
RA patients, B19V DNA positive or negative) had IgG
class antibodies to VP2 protein; however they did not
have IgM class antibodies. Part of the plasma samples
(55 from RA patients and 28 from healthy persons)
were analysed using the Mikrogen Diagnostik’s recom-
Line dot blot kit. According to manufacturer’s (Mikro-
gen Diagnostik) manual, recomLine dot blot enables
determination of antibodies to the various virus anti-
gens: VP-2P (main capsid antigen, conformation epi-
tope), VP-N (the N-terminal half of the structural
proteins VP1 and VP2), VP-1S [corresponds to the
unique region of VP1 (VP1u)], VP-2r (main capsid
antigen, linear epitope), VP-C (the C-terminal half of
the structural proteins VP1 and VP2) and NS-1 (non-
structural protein) (Pfrepper et al., 2005). VP-2P protein
in recomLine dot blot corresponds to the VP2 protein
in Biotrin ELISA. Although IgG ELISA seems to be
more sensitive [77 samples out of 83 were positive in
IgG VP2 ELISA, whereas only 59 samples out of 83
were positive in IgG VP-2P dot blot (Table S2)], the
results obtained using Biotrin VP2 IgG ELISA and
recomLine with IgG VP-2P dot blot are comparable
according to the Spearman’s correlation test (r=0.909,
P<0.0001). The IgG class antibodies to VP2/VP-2P pro-
teins were detected in the plasma of majority of RA
patients’ and controls’ plasma samples (to VP2 in 91%
of RA B19+, 94% of RA B19 , 79% of B19+ controls
and 100% of B19  controls; to VP-2P in 77% of RA
B19+, 67% of RA B19 , 78% of B19+ controls and
68% of B19  controls). The seroprevalence of IgG anti-
bodies to VP2/VP-2P did not differ significantly between
the groups of RA patients and healthy controls. How-
ever, the seroprevalence of IgG antibodies to VP-N and
VP-1S was different between RA B19+b and RA B19+p
patients. In the RA B19+b group, 80% of patients had
IgG antibodies to VP-N and VP-1S, while in the RA
B19+p group, only 46 and 38% of patients had antibod-
ies to VP-N and VP-1S, respectively. Only a limited
number of persons had IgG antibodies to VP-2r (five
RA B19+, five RA B19  and three B19  controls), VP-C
(one RA B19  and one B19  control) and NS-1 (two
B19  controls) (see Tables 3 and S2). Although we did
not detect IgM antibodies to VP2 protein by ELISA in
the plasma of RA patients and healthy controls, recom-
Line dot blot assay showed the presence of IgM class
antibodies in some RA patients. IgM antibodies to VP-
2P were detected in the plasma of 11, to VP-N in 7
and to VP-1S and VP-2r in 2 RA patients (Table S2).
IgM antibodies to the proteins mentioned were not
detected in the plasma of healthy controls (Tables 3 and
S1). The presence of IgM class antibodies in RA did not
show an association with the presence of B19 DNA in
plasma or whole blood.
Table 1. Presence of B19V genomic sequence in the blood DNA of RA patients and healthy persons
The values marked by stars are significant according to Fisher’s exact tests: *P<0.05, **P<0.0005. B19V, Parvovirus B19; B19+, parvovirus B19
DNA positive; B19 , parvovirus B19 DNA negative; RA, rheumatoid arthritis; Contr., healthy persons.
Investigated
persons (total)
Age±SD (years) B19+ samples B19  samples






N % TotalN % Total N % Total N % Total N % Total
Females
Contr. 37 50.3±10.4 6 16.2 1 2.7 0 0 7 18.92 30 81.08
RA 99 57.3±13.0 6 6.1 12 12.1 6 6.1 24 24.24 75 75.76
Males
Contr. 12 49.8±13.8 2 16.66 0 0 0 0 2 16.66 10 83.33
RA 19 63.5±12.7 0 0 4 21.1 2 10.5 6 31.58 13 68.42
All investigated (males+females)
Contr. 49 50.2±11.3 8 16.3** 1 2.0* 0 0 9 18.37 40 81.63
RA 118 58.3±13.0 6 5.1** 16 13.6* 8 6.8 30 25.42 88 75.58
M. Naciute and others
3304 Journal of General Virology 97
Levels of IL-6 in the plasma of RA patients and
healthy controls
The levels of IL-6 were determined in the blood plasma of
all investigated RA patients and controls. The levels of IL-6
were significantly higher in the plasma of RA patients (25.0
±33.6 pgml 1 in B19+ group and 19.0±30.5 pgml 1 in
B19  group) in comparison with the persons in the control
group (0.8±1.0 pgml 1 in B19+ group and 1.6±3.4 pgml 1
in B19  group) (Fig. 1a). There were no significant differ-
ences between the plasma level of IL-6 in B19+ and B19 
controls. However, RA B19+ patients had significantly
higher average levels of IL-6 than RA B19  patients. Impor-
tantly, we found that the IL-6 levels were particularly
increased in RA B19+p patients’ group (40.6±39.7 pgml 1)
(Fig. 1b). The levels of IL-6 in patients from the RA B19+b
and RA B19+b/p groups were 7.2±9.8 and 7.0±5.9 pgml 1,
respectively. Our data showed that some clinical data (anti-
CCP, DAS28, HgB and ESR) differ when B19V DNA was
detected in the plasma (Table 2). Therefore, the cytokine
levels were analysed according to the findings in respect of
clinical parameters. The levels of IL-6 in the plasma of RA
B19+ patients were investigated according to RA disease
activity. The patients were divided according to DAS28 in
two groups: DAS28<5.2 (low disease activity or remission)
and DAS28>5.2 (high disease activity) (Fig. 1c). Fig. 1(c)
shows that the level of IL-6 is increased in RA B19+p
patients with DAS28>5.2 (IL-6 54.4±40.7 pgml 1), but not
in patients with DAS28<5.2 (IL-6 10.6±11.4 pgml 1). Also,
the RA patients were divided into groups according to HgB
levels. The levels of IL-6 were similarly low in all B19+ and
B19  RA patients’ groups with normal values of HgB. How-
ever, the levels of IL-6 were increased in RA B19+p patients
with lower values of HgB. IL-6 concentration in the plasma
of RA B19+p patients was 61.6±43.6 pgml 1 when the level
of HgB was low and 19.7±21.8 pgml 1 when the level of
HgB was normal (Fig. 1d). We investigated IL-6 levels in RA
patients according to CRP level (Fig. 1e). The IL-6 concen-
tration in the plasma was lower in B19+p RA patients with
normal levels of CRP (IL-6 12.7±10.0 pgml 1). RA B19+p
patients with increased CRP levels had increased IL-6 con-
centrations (IL-6 53.4±41.9 pgml 1) in comparison with
Table 2. Clinical characteristics of rheumatoid arthritis patients
Table 2 shows the number of patients with normal values (norm.), higher than normal (>norm.), lower than normal (<norm.) or with appropriate
indicated values. The percentage of patients with indicated parameters are shown. WBC, White blood cells; HgB, haemoglobin; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; anti-CCP, cyclic citrullinated peptide antibody; DAS28, disease activity score; RF, rheumatoid
factor.
Clinical data Parvovirus B19 DNA positive in Parvovirus B19
DNA negative
Blood and plasma Blood Plasma
WBC (109 l 1) Norm. 5 3 11 46
>Norm. 3 3 5 42
% >Norm. 37.5 50.0 31.3 47.7
HgB (g l 1) Norm. 3 4 5 48
<Norm. 5 2 11 40
% <Norm. 62.5 33.3 68.8 45.5
ESR (mm h 1) Norm. 3 3 2 19
>Norm. 5 3 14 68
% >Norm. 62.5 50.0 87.5 77.3
CRP (mg l 1) Norm. 3 2 5 22
>Norm. 5 4 11 66
% >Norm. 62.5 66.7 68.8 75.0
Anti-CCP (EUml 1) 1–60 6 4 5 45
>60 2 2 11 43
% >60 25.0 33.3 68.8 48.9
DAS28 <5.2 4 5 5 43
>5.2 4 1 11 43
% >5.2 50.0 16.7 68.8 50.0
Disease duration (years) 0–10 5 2 8 44
>10 3 4 8 44
% >10 37.5 66.7 50.0 50.0
RF (Uml 1) 1–100 3 3 9 50
>100 5 3 7 38
% >100 62.5 50.0 43.8 44.0















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M. Naciute and others
3306 Journal of General Virology 97
RA B19+b/p, B19+b and B19  patients’ groups (the average
IL-6 concentration varied from 1.8 to 12 pgml 1). The con-
centrations of IL-6 were significantly higher also in RA B19+
and RA B19 patients’ groups that fulfilled the following
criteria: low HgB, high ESR, DAS28>5.2 in comparison to
RA B19+ and RA B19 patients’ groups that have normal
HgB, normal ESR and DAS28<5.2 (Fig. S1). The IL-6 con-
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Fig. 1. Amount of IL-6 in the plasma of parvovirus B19 DNA positive (B19+) and parvovirus B19 DNA negative (B19 ) per-
sons. IL-6 in the plasma of rheumatoid arthritis (RA) patients and healthy age-matched persons (control) (a). IL-6 in the plasma
of RA patients, divided according to the localization of virus DNA (b). RA patients are divided into the groups according to the
findings of virus DNA (in blood, in cell-free blood plasma and in both blood and cell-free plasma) and DAS28<5.2 and
DAS28>5.2 (c); HgB lower than normal and HgB normal (d); normal values of CRP and CRP high (e) and patients with and
without immunotherapy (f). One symbol shows the amount of IL-6 (pgml 1) of one person. Results are significant according to
Mann–Whitney U test: *P<0.05, **P<0.005 or ***P<0.0005.
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account the method of treatment. The concentration of IL-
6 was higher (46.6±41.5 pgml 1) in RA B19+p patients
without immunotherapy. However, RA B19+p patients after
immunotherapy had lower (14.8±16.0 pgml 1) levels of IL-
6. IL-6 plasma levels in RA B19+b and RA B19+b/p patients
were low, whether or not they had had immunotherapy (up
to 14 pgml 1) (Fig. 1f). The patients were divided into dif-
ferent groups with low, normal or high values of WBC,
ESR, anti-CCP and RF. The level of IL-6 was increased in
the RA B19+p patients group, but we did not observe signifi-
cant differences in the concentration of IL-6 by comparing
B19+p RA patients with normal or increased/decreased val-
ues of WBC, ESR, anti-CCP and RF (Fig. S2). Also, we did
not find significant changes in IL-2, IL-4, IL-10, IL-12, IL-
17, TNF-a and IFN-g levels in the plasma of RA B19+p
patients (Table S3). Next, we analysed the correlation
between cytokine concentrations in the plasma and clinical
parameters according to the B19V DNA localization
(Table S4). We observed some significant correlations that
were characteristic only of patients from RA B19+p group.
There were positive correlations between IL-2 and IL-12
levels (r=0.91, P<0.0005), IL-10 and IL-12 levels (r=0.71,
P<0.005), IL-12 level and disease duration (r=0.54, P<0.05),
IL-12 level and DAS28 (r=0.53, P<0.05), IL-10 level and
CRP concentration (r=0.6, P<0.05), IL-6 level and CRP
concentration (r=0.7, P<0.005) and IFN-g level and CRP
concentration (r=0.58, P<0.05). Negative correlations were
observed between IL-4 and HgB levels (r= 0.5, P<0.05)
and IL-6 and HgB levels (r= 0.69, P<0.005). Such correla-
tions were not observed when B19V DNA was detected in
blood and plasma, or blood or not detected at all.
We calculated correlations between amount of antibodies
and levels of cytokines for various indices of clinical data.
We found significant negative correlations between the
amount of antibodies to VP-C and levels of IL-6 in plasma
(r= 0.6, P<0.05), between antibodies to VP-N, VP-1S, VP-
2r and age (r= 0.6, P<0.05) and between antibodies to VP-
2r and RF (r= 0.59, P<0.5). A significant positive correla-
tion was noticed between levels of antibodies to VP2 and
levels of IFN-g (r=0.59, P<0.5). Such correlations were
observed only in RA B19+p patients and were not noticeable
in the groups of RA B19+b, RA B19+b/p, RA B19 , control
B19+ and control B19  persons.
DISCUSSION
B19V infection in RA patients was investigated in this study.
Our results show that the presence of B19V DNA is more fre-
quent in RA patients than in age- and sex-matched people
that do not have RA and do not suffer from the pain in the
joints. In addition, in contrast to persons in the control group
where B19V DNA is found mostly in whole blood (persistent
infection in latent phase), the majority of B19V DNA-positive
RA patients have virus DNA in cell-free blood plasma, i.e.
they have persistent infection in the active phase. Our data
coincide with previously published data, in showing that the
prevalence of B19V DNA in serum, plasma or peripheral
blood cells was significantly higher in patients with RA than in
controls (Caliskan et al., 2005; Chen et al., 2006; Kozireva
et al., 2008; Tzang et al., 2009b) and that RA activity was
higher in patients with latent/persistent B19V infection
(Kakurina et al., 2015). However, some authors concluded
that B19V is not involved in the aetiopathogenesis of RA
(Kerr et al., 1995; Nikkari et al., 1995). Paradoxically, we find
that B19V DNA is present only in the cell-free blood plasma
of some RA patients but not in their whole blood which also
includes plasma. This could be due to low copies of virus
DNA in the plasma. When DNA is isolated from the cell-free
plasma, viral DNA is concentrated and could be detectable.
However, when DNA is purified from whole blood, the
majority of the DNA comes from blood cells, and the viral
DNA (present in plasma) is diluted and is not detectable due
to low copies and insufficient PCR sensitivity. Therefore, it is
most likely that the B19V DNA detected in whole blood rep-
resents viral DNA from B19V containing blood cells. More-
over, the presence of B19V DNA in peripheral blood cells has
been shown previously by Kakurina et al. (2015), while the
presence of VP1 protein in synovial cells including lympho-
cytes, macrophages and neutrophils (e.g. cells present in the
blood) was shown by Takahashi et al. (1998).
Since B19V DNA in RA patients dominates in the plasma,
we analysed how it affects the clinical data, the antibody
response to various virus proteins and the levels of cytokine
expression in the blood. Our data show that RA patients
with B19V DNA in cell-free plasma have also higher levels
of anti-CCP and higher scores of DAS28, indicating higher
disease aggressiveness and activity, respectively. Many of
the RA patients with B19V DNA sequences in plasma DNA
also have decreased HgB (68.8%) and increased ESR
(87.5%), in comparison with the RA patients who have
virus sequences in whole blood DNA or do not have it at
all. This is consistent with previously known data that per-
sistent B19V infection in humans may cause chronic an-
aemia (Kurtzman et al., 1989) and, as our data suggest, that
B19V may play a certain role in the pathogenesis of RA.
Although the majority of RA patients in our study have IgG
class B19V-specific antibodies, the spectrum of antibodies
varies. A smaller percentage of RA B19+p patients, com-
pared with healthy controls or RA B19+b patients, have VP-
1S- and VP-2P-specific antibodies. VP-1S and VP-N anti-
gens overlap with the unique region of VP1. It is known
that the epitopes of neutralizing antibodies are located
within the VP1u and VP1–VP2 junction regions (Saikawa
et al., 1993), and also within the amino-terminal portion of
VP2 (Sato et al., 1991). Neutralizing antibodies are pro-
duced shortly after infection (von Poblotzki et al., 1995)
and elicit a long-lasting immune response (Zuffi et al.,
2001). The production of neutralizing antibodies to VP1u is
very important for immune protection against viral infec-
tion, while VP1u is essential for B19V binding and internal-
ization (Leisi et al., 2013). In our study, the lack of
neutralizing antibodies in RA B19+p patients could explain
the higher frequency of B19V persistent infection in the
active phase or viraemia (cell-free virus in the blood
M. Naciute and others
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stream), because the production of neutralizing antibody to
capsid protein in persistently infected subjects plays a major
role in limiting B19V infection in human (Kurtzman et al.,
1989). B19+p RA patients differ from other (B19+b/p,
B19+b and B19 ) RA patients and from healthy controls, in
that not only do the majority of them not have antibodies
to VP-1S and VP-N, but also in that the amount of antibod-
ies to VP-N, VP-1S and VP-2r negatively correlates with
age, the amount of antibodies to VP-2r negatively correlates
with RF, the amount of antibodies to VP-C negatively cor-
relates with levels of IL-6 and HgB values negatively correl-
ate with levels of IL-4 and IL-6. Antibodies to VP-2P and
VP2 positively correlate with WBC and IFN-g, respectively.
Positive correlations were observed between the levels of IL-
2 and IL-12, IL-10 and IL-12, IL-12 and disease duration,
IL-12 and DAS28, IL-10 and CRP, IL-6 and CRP and IFN-g
and CRP. Such correlations were not observed in other
groups of RA patients and healthy persons. The presence of
these correlations, in the RA B19+p patient group only, also
indicates that B19V plays a role in RA pathogenesis.
Our data and previous (Manicourt et al., 1993; Stabler et al.,
2004) data show that levels of IL-6 are increased in the serum
of patients with RA compared with controls. Our data indi-
cate significantly increased IL-6 concentrations in the plasma
of B19V-infected RA patients, but only in those who have a
virus genomic sequence in cell-free plasma DNA. The levels
of IL-6 in RA B19+b and RA B19+b/p patients are even lower
than in RA B19  patients, and are similar to levels in the
plasma of healthy controls. Also, IL-6 levels are increased in
RA patients with DAS28>5.2, low HgB and high CRP and in
those not receiving immunotherapy.
Serum IL-6 level as a potential biomarker reflecting RA dis-
ease activity is described previously (Shimamoto et al.,
2013). B19V infection also could cause the increased IL-6
concentration in blood. Increased levels of IL-6 mRNA or
increased serum IL-6 levels are detected during acute B19
infection, but not by follow-up (Kerr et al., 2001, 2004).
The levels of IL-6 are raised in B19-infected patients with
chronic fatigue syndrome (Chapenko et al., 2012).
It is shown that B19V proteins NS1 (Hsu et al., 2006; Kerr
et al., 2001) and VP1u (Tzang et al., 2009a) induce IL-6
mRNA expression. B19V proteins during viraemia could
induce IL-6 production in RA patients. Takahashi et al.
(1998) have shown in vitro that B19V induced IL-6 produc-
tion could be suppressed by the addition of neutralizing
anti-VP1 antibody. However, the majority of RA patients
do not have neutralizing antibodies to the VP1N-terminal
part, and this could be a reason for B19V infection activity
and increased levels of IL-6 in blood. The active phase of
persistent B19V infection in RA patients is associated with
increased disease activity, an increased amount of anti-
CCP, decreased HgB and increased ESR. In summary, our
study suggests that B19V infection, at least in some patients,
plays a role in pathogenesis of RA.
METHODS
Blood samples of patients. A total of 118 patients with RA (99
females and 19 males, mean age 58.3±13.0 years) and 49 age- and sex-
matched healthy volunteers (37 females and 14 males, mean age 50.2
±11.3 years) as the control group were enrolled in this study. Partici-
pants in the study were selected from patients seen at the Vilnius Uni-
versity Hospital Santariskiu Clinics. RA was diagnosed according to
2010 ACR/EULAR (American College of Rheumatology/ European
League Against Rheumatism) RA Classification Criteria for the classifi-
cation of RA by expert rheumatologists (Cotmore et al., 1986). We did
not include chronic (over 6months) B19V-induced polyarthritis with
transient RF in this study as RA. Also, reactive arthritis induced by par-
vovirus infection does not fulfil the RA Classification Criteria for the
classification of RA. RA group patients were treated by immunosupres-
sants. Some of the RA patients have comorbidities (e.g. cardiovascular
diseases). All patients underwent an extensive medical examination,
whole blood analysis and extensive serologic evaluation which included
tests for WBC, HgB, ESR, CRP, anti-CCP, DAS28 and RF. Blood sam-
ples were collected in vacutainers with K2EDTA and processed within
4 h of collection. The whole blood samples at aliquots of 0.5ml and the
plasma samples at aliquots of 0.2ml were frozen and stored at  80

C
until used for analysis.
This study was approved by the Vilnius Regional Biomedical Research
Ethics Committee.
DNA extraction and PCRs. DNA was isolated from 0.5ml of the
whole blood and from 0.2ml of cell-free plasma. The sample was
digested by proteinase K and extracted by a standard phenol–chloro-
form technique. B19V genomic DNA was detected by a nested PCR.
The sequences of B19V primers were as described by Durigon
et al. (1993). The sequences of the primers were: F-out AATACACTG
TGGTTTTATGGGCCG, R-out CCATTGCTGGTTATAACCACAGGT;
F-in GAAAACTTTCCATTTAATGATGTAG, R-in CTAAAATGGC
TTTTGCAGCTTCTAC. The PCR was performed using Maxima Hot
Start Polymerase (Thermo Scientific) according to the manufacturer’s
recommendations. Positive and negative (DNA without B19V genomic
sequences) controls were included in every PCR as well as water controls
after every third sample. The cycling conditions of the first reaction
were: 95

C 10min, 40 cycles: 95

C 45 s, 55






C 2min. Two microlitres of the product from first PCR
was subjected to the second reaction of PCR. The cycling conditions of
the second reaction were the following: 95






C 45 s, 75

C 45 s and elongation 75

C 2min. The PCR prod-
ucts (284 bp) were analysed in 3% agarose gel.
Detection of antibodies to B19V antigens. IgM and IgG antibodies
to B19V antigens were detected in blood plasma. Antibodies to VP2 pro-
tein were detected using Parvovirus B19 IgM and IgG Enzyme Immuno-
assay kits (Biotrin). The assays were performed and the results were
calculated according to the manufacturer’s instructions. Data compari-
son between different assay runs was facilitated by using an index value.
The index was calculated as the ratio of the sample’s optical density (or
OD450 nm) measurements to the cutoff’s OD450 nm. An index value <0.9
or >1.1 indicated sample negativity or positivity, respectively. Equivocal-
ity was indicated if the index value was in the range 0.9–1.1.
The antibodies to various virus proteins were determined using recom-
Line Parvovirus B19 IgG and IgM kits (Mikrogen). IgM and IgG class
antibodies to VP-2P (main capsid antigen, conformation epitope), VP-
N (N-terminal half of the structural proteins VP1 and VP2), VP-1S
(VP1u), VP-2r (main capsid antigen, linear epitope), VP-C (C-terminal
half of the structural proteins VP1 and VP2) and NS-1 (non-structural
protein) were determined. The assays were performed according to the
manufacturer’s instructions. The bands of the blots were scanned and
the band density was quantified using ImageJ 1.49 software.
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Determination of the cytokine concentration in the plasma. The
IL-2, IL-4, IL-6, IL-10, IL-12, IL-17 and TNF-a levels in the plasma
were detected using human IL-2, IL-4, Il-6, IL-10, IL-12 (p70), IL-17
and TNF-a ELISA MAX Standard Sets (BioLegend) according to the
manufacturer’s recommendations. The IFN-g level was detected by
two-site ELISA using home-made murine mAbs to human IFN-g and
recombinant human IFN-g (Life Technologies), as the standard as
described before (Voll et al., 1997). The plasma for ELISA was diluted
1 : 3. The results were calculated using ‘Gen5’ software.
Statistical analysis. Fisher’s exact test was used to calculate rates and
proportions between the groups. Mann–Whitney U test was used to
compare two groups of patients with non-normal distribution of data.
The Spearman’s rank correlation coefficient was used to discover the
strength of correlation between two sets of data. P<0.05 was considered
significant.
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